Therapy Area Reports

Learn More CAR-T Therapy in Haematological Malignancy: Update Bulletin [July 2017]

This edition presents US and EU key opinion leader (KOL) views on recent developments in the CAR-T therapy space. Topics covered include expert opinions on Novartis receiving a positive recommendation from the...

Compare
Learn More COPD: Update Bulletin [July 2017]

Gain new key opinion leader (KOL) insights on the latest events happening in COPD. Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate), delivered via PARI's investigational eFlow...

Compare
Learn More Ovarian Cancer: Update Bulletin [July 2017]

This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib)...

Compare
Learn More Prostate Cancer: Update Bulletin [July 2017]

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...

Compare
Learn More Targeted Therapies in Asthma: Update Bulletin [July 2017]

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape. Topics covered include; Novartis...

Compare
Learn More Colorectal Cancer: Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the Colorectal Cancer (CRC) market. Topics covered include: Bristol-Myers Squibb (BMS) announcing interim data from the Phase II,...

Compare
Learn More Rheumatoid Arthritis: Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of rheumatoid arthritis (RA). Topics covered include; KOL views on the Food and Drug Administration’s issuance of a...

Compare
Learn More Ulcerative Colitis: Update Bulletin [June 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world...

Compare
Learn More Type 2 Diabetes Mellitus KOL Insight : Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line results from the Phase...

Compare
Learn More Payer Insights: RA : Update Bulletin [May 2017]

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara...

Compare
Learn More Hepatitis C Virus KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating an update on the results of its triple...

Compare
Learn More Multiple Sclerosis: Update Bulletin [May 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus (ocrelizumab,...

Compare
Learn More Melanoma: KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma announcing that it has withdrawn its New Drug Application (NDA)...

Compare
Learn More Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [May 2017]

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Coverage includes KOL opinions about the Phase III results...

Compare
Learn More NSCLC: KOL Insight: Update Bulletin [May 2017]

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment...

Compare
Learn More AML: KOL Insight: Update Bulletin [May 2017]

This update bulletin presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include: Novartis receiving US FDA approval for Rydapt (midostaurin)...

Compare
Learn More Cystic Fibrosis: KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data from a Phase II study for...

Compare
Learn More HNSCC: KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of head and neck small cell carcinoma (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers...

Compare
Learn More Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American Academy...

Compare
Learn More Multiple Sclerosis - Payer Insight: Update Bulletin [April 2017]

Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis...

Compare

Browse by